New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
07:38 EDTPGNXProgenics acquires Molecular Insight Pharmaceuticals in all-stock deal
Progenics Pharmaceuticals announced that it has acquired Molecular Insight Pharmaceuticals, a clinical-stage private biotechnology company with a small molecule chemistry pipeline aimed at enhancing cancer treatment. Under the terms of the all-stock transaction, Progenics exchanged 4,566,210 shares of its common stock, or 8.9% of the total outstanding post-transaction shares, for all of the outstanding shares of Molecular Insight, which will become a wholly-owned subsidiary of Progenics. Molecular Insight has no debt. Progenics may make additional milestone payments to the former owners of Molecular Insight based on future commercial sales of the company's compounds. No royalties are due to the former owners of Molecular Insight. Key elements of Molecular Insight's pipeline include targeted radiotherapy and molecular imaging compounds.
News For PGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:18 EDTPGNXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use